Related Experiment Video

Updated: Aug 16, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 10, 2014

Virologic and immunologic values allowing safe deferral of antiretroviral therapy

John P Phair1, John W Mellors, Roger Detels

  • 1Division of Infectious Diseases, Department of Medicine, Northwestern University Medical School and the Howard Brown Health Center, 676 N. St. Clair, Suite 200, Chicago, IL 60611, USA.

AIDS (London, England)
|December 4, 2002
PubMed

Insights

Highly active antiretroviral therapy can be safely deferred for HIV-1 infected individuals with specific CD4 counts and viral loads. Close monitoring allows many patients to delay treatment without disease progression.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Virology

Background:

  • HIV-1 infection management involves complex decisions regarding antiretroviral therapy initiation.
  • Highly active antiretroviral therapy (HAART) significantly impacts disease progression but carries potential side effects.
  • Determining optimal timing for HAART initiation is crucial for balancing treatment benefits and risks.

Purpose of the Study:

  • To investigate the safety of deferring highly active antiretroviral therapy (HAART) in HIV-1 infected individuals.
  • To establish criteria for delaying HAART based on CD4 cell counts and HIV viral load.
  • To inform clinical guidelines on when to initiate antiretroviral treatment for HIV-1.

Main Methods:

  • An observational cohort study was conducted involving HIV-1 infected men across four academic centers in the USA.
  • The study monitored progression to clinical AIDS or CD4 cell counts below 200 x 10(6)/l in participants not receiving antiretroviral therapy.
  • Data analysis focused on correlating baseline CD4 counts and HIV RNA levels with clinical outcomes over time.

Main Results:

  • No progression to AIDS was observed within one year for individuals with CD4 counts between 201-350 x 10(6)/l and HIV RNA < 20,000 copies/ml.
  • Similarly, no AIDS progression occurred within one year for those with CD4 counts > 350 x 10(6)/l and HIV RNA < 60,000 copies/ml.
  • A small percentage (3%) of individuals with CD4 > 350 x 10(6)/l and HIV RNA < 30,000 copies/ml experienced a CD4 count decrease to < 200 x 10(6)/l within one year.

Conclusions:

  • Deferring HAART is supported for HIV-1 infected individuals with CD4 counts > 350 x 10(6)/l and HIV RNA < 60,000 copies/ml.
  • Therapy deferral is also advisable for those with CD4 counts between 201-350 x 10(6)/l and HIV RNA < 20,000 copies/ml.
  • With close monitoring, a significant proportion of patients can safely defer HAART, potentially up to 79% in certain groups.
Abstract

More Related Videos

Humanized NOD/SCID/IL2r&#947;null (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...